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Cost-effectiveness of Screening for Osteoporosis
in Older Men With a History of Falls
Kouta Ito, MD, MS
Abstract
IMPORTANCE Falls and osteoporosis share the potential clinical end point of fractures among older
patients. To date, few fall prevention guidelines incorporate screening for osteoporosis to reduce
fall-related fractures.
OBJECTIVE To assess the cost-effectiveness of screening for osteoporosis using dual-energy x-ray
absorptiometry (DXA) followed by osteoporosis treatment in older men with a history of falls.
DESIGN, SETTING, AND PARTICIPANTS In this economic evaluation, a Markov model was
developed to simulate the incidence of major osteoporotic fractures in a hypothetical cohort of
community-dwelling men aged 65 years who had fallen at least once in the past year. Data sources
included literature published from January 1, 1946, to July 31, 2020. The model adopted a societal
perspective, a lifetime horizon, a 1-year cycle length, and a discount rate of 3% per year for both
health benefits and costs. The analysis was designed and conducted from October 1, 2019, to
September 30, 2020.
INTERVENTIONS Screening with DXA followed by treatment for men diagnosed with osteoporosis
compared with usual care.
MAIN OUTCOMES AND MEASURES Incremental cost-effectiveness ratio (ICER), measured by cost
per quality-adjusted life-year (QALY) gained.
RESULTS Among the hypothetical cohort of men aged 65 years, the screening strategy had an ICER
of $33 169/QALY gained and was preferred over usual care at the willingness-to-pay threshold of
$100 000/QALY gained. The number needed to screen to prevent 1 hip fracture was 1876; to prevent
1 major osteoporotic fracture, 746. The screening strategy would become more effective and less
costly than usual care for men 77 years and older. The ICER for the screening strategy did not
substantially change across a wide range of assumptions tested in all other deterministic sensitivity
analyses. At a willingness-to-pay threshold of $50 000/QALY gained, screening was cost-effective in
56.0% of simulations; at $100 000/QALY gained, 90.8% of simulations; and at $200 000/QALY
gained, 99.6% of simulations.
CONCLUSIONS AND RELEVANCE These findings suggest that for older men who have fallen at
least once in the past year, screening with DXA followed by treatment for those diagnosed with
osteoporosis is a cost-effective use of resources. Fall history could be a useful cue to trigger
assessment for osteoporosis in men.
JAMA Network Open. 2020;3(12):e2027584. doi:10.1001/jamanetworkopen.2020.27584
Key Points
Question Is it cost-effective to screen
for osteoporosis in older men with a
history of falls?
Findings In this model-based economic
evaluation of a hypothetical cohort of
men aged 65 years, screening with dual-
energy x-ray absorptiometry followed
by treatment for those diagnosed with
osteoporosis had an incremental cost-
effectiveness ratio of $33 169 per
quality-adjusted life-year gained and
was preferred over usual care at the
willingness-to-pay threshold of
$100 000 per quality-adjusted life-
year gained.
Meaning These findings suggest that,
for older men who have fallen at least
once in the past year, screening with
dual-energy x-ray absorptiometry
followed by treatment for those
diagnosed with osteoporosis is a cost-
effective use of resources.
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Introduction
Falls and osteoporosis are geriatric syndromes that share the potential clinical end point of fractures.1
Approximately 1 in 4 men 65 years or older fall each year in the United States, making falls a public
health concern, particularly among older adults.2 Prevalence of osteoporosis also increases with age,
affecting an estimated total of 2 million men.3 By 2030, the number of hip fractures in men is
projected to increase to 109 000 each year.4 Hip fractures are overwhelmingly precipitated by falls.5
Many older men at risk for falls are predisposed to fractures by undetected osteoporosis.6-9 It
therefore makes clinical sense to screen for osteoporosis as a part of routine fall prevention care.
Performing dual-energy x-ray absorptiometry (DXA) in those who have fallen could be crucial
because a history of falls does not necessarily indicate osteoporosis and a need for osteoporosis
treatment. To date, few fall prevention guidelines incorporate screening for osteoporosis to reduce
fall-related fractures.10-12 Although several professional organizations have advocated routine
screening for osteoporosis in older men, the US Preventive Services Task Force continues to conclude
that evidence was insufficient to justify this practice.13-16 Medicare coverage for DXA is rather
restrictive in men unless they have known skeletal abnormalities or secondary causes of
osteoporosis.17 Despite a predicted rise in the number of hip fractures, osteoporosis remains
underdiagnosed and undertreated in men.18 Recent clinical trials suggested that population-based
screening for osteoporosis could reduce hip and osteoporotic fractures in older women.19-22 A similar
clinical trial would be ideal to evaluate the efficacy of a screening practice in older men but unrealistic
because of the need for a larger sample size. Accordingly, we developed a simulation model to
evaluate the long-term health and economic effect of screening with DXA followed by treatment for
those diagnosed with osteoporosis in older men with a history of falls.
Methods
Overview and Model Structure
For this economic evaluation study, a Markov model was developed to simulate the prognosis of
older men with a history of falls in the last year based on previously published models of screening for
osteoporosis and the guideline by the European Society for Clinical and Economic Aspects of
Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases and the US branch of the International
Osteoporosis Foundation (Figure 1).23-27 Health states were determined by a history of major
osteoporotic fractures to represent those who experienced any combination of different types of
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All men entered the model in the fracture-free state. At
the decision node, they were assigned to either usual
care or screening. They had osteoporosis or no
osteoporosis at baseline. Osteoporosis treatment was
provided only if they were diagnosed with
osteoporosis by screening and adherent to
recommended therapy. Each year, they were at risk for
sustaining a fracture or dying of other causes. If they
sustained hip or clinical vertebral fractures, they were
at risk of dying due to those fractures. Depending on
an event experienced, they remained in the fracture-
free state, proceeded to the postfracture states, or
were absorbed into the dead state. In the actual
model, the post–multiple fracture state was separated
into 15 health states representing any combinations
of different types of fractures. DXA indicates dual-
energy x-ray absorptiometry.
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fractures. Data sources included literature published from January 1, 1946, to July 31, 2020. The
model adopted a societal perspective, a lifetime horizon, a 1-year cycle length, and a discount rate of
3% per year for both health benefits and costs.28 The analysis was performed by using TreeAge Pro
Suite 2018 software, version 18.2.1-v20180828 (TreeAge Software). This study follows the
recommendations of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS)
reporting guideline.29
Population
The model targeted a hypothetical cohort of US community-dwelling men aged 65 years who had
fallen at least once in the past year. It was assumed that all men were fracture free at baseline.
Interventions
Men were assigned to either usual care or screening for osteoporosis. Those who were assigned to
usual care underwent no screening for osteoporosis. Those who were assigned to screening for
osteoporosis underwent DXA of the femoral neck and the lumbar spine and received treatment if
they were diagnosed with osteoporosis. Osteoporosis was defined as a T score of bone mineral
density (BMD) of less than −2.5 at either site using the reference for White women aged 20 to 29
years from the National Nutrition and Examination Survey (NHANES) III.30 An alternate scenario
using the reference for White men aged 20 to 29 years was also tested in a scenario analysis.
Alendronate sodium (70 mg orally once a week for 5 years) was selected as a drug of choice when
osteoporosis treatment was indicated. An alternate scenario selecting zoledronic acid (5 mg
intravenously once a year for 5 years) as a drug of choice was also tested in a scenario analysis. We
assumed that a basic metabolic panel was ordered and comprehensive oral examination was
performed before initiation of zoledronic acid therapy. Those receiving osteoporosis treatment were
assumed to require an additional physician visit each year during a 5-year course of therapy and to
incur the cost of DXA in the second and fourth year after treatment initiation.23,26,31 We also assumed
that both groups were offered the same fall prevention measures and received a daily
supplementation of calcium (1200 mg) and vitamin D (800 IU).
Input Parameters
Model parameters are summarized in Table 1 and eTable in the Supplement and described in detail
below. Prevalence of osteoporosis, incidence of fractures, and utility for a fracture-free state were
age dependent. Other parameters were considered as constant for each age group.
Prevalence of Osteoporosis
The age-dependent prevalence of osteoporosis was based on a cross-sectional study from the 2005-
2010 NHANES.3 The cohort studies from 3 countries6-8 did not observe a significant difference in
BMD among men with and without a history of falls. Therefore, we assumed that the prevalence of
osteoporosis was not affected by a history of falls or the number of falls in the previous year. The
base-case estimate of the prevalence of osteoporosis was altered widely in sensitivity analyses.
Incidence of Fractures
The age-dependent fracture rates were obtained from hospital discharge data from the Healthcare
Cost and Utilization Project Nationwide Inpatient Sample.52,53 The model modified the fracture rates
based on a history of falls, the presence of osteoporosis, and a history of fractures. The relative risks
of fractures associated with a history of falls were taken from a meta-analysis of cohort studies from 3
countries.9 Pooled data from men with a history of a single fall and multiple falls were obtained and
were assumed to last as long as 10 years. An alternate scenario considering the number of falls was
also tested in a scenario analysis. The relative risks of fractures stratified by the number of falls (ie, 1,
2, or 3) in the past year were based on the combined data for men and women from a cohort study
in Canada.8 The relative risks of fractures associated with the presence of osteoporosis were
JAMA Network Open | Geriatrics Cost-effectiveness of Screening for Osteoporosis in Older Men With a History of Falls
JAMA Network Open. 2020;3(12):e2027584. doi:10.1001/jamanetworkopen.2020.27584 (Reprinted) December 1, 2020 3/13
Downloaded From: https://jamanetwork.com/ by a University of Massachusetts User  on 02/16/2021
Table 1. Model Parameters
Parameter Value (range) Distribution Source
Discount rate, % 3 (0-6) Not applied Neumann et al28 (2016)
Prevalence of osteoporosis, %a 3.3 (1.98-4.62) Beta Wright et al3 (2014)
Relative risk of hip fractures associated
with a history of falls
Base case 1.54 (1.21-1.95)
Log-normal
Leslie et al8 (2019) and
Harvey et al9 (2018)
1 Fallb 1.51 (1.06-2.15)
2 Fallsb 1.88 (1.12-3.16)
≥3 Fallsb 3.41 (2.19-5.31)
Relative risk of nonhip fractures
associated with history of falls
Base case 1.51 (1.32-1.73)
Log-normal
Leslie et al8 (2019) and
Harvey et al9 (2018)
1 Fallb 1.44 (1.23-1.67)
2 Fallsb 1.65 (1.31-2.08)
≥3 Fallsb 2.52 (2.05-3.11)
Relative risk of fractures associated
with the presence of osteoporosis
Hip 5.98 (3.50-9.06)
Log-normal
Looker et al32 (2012) and
Johnell et al33 (2005)
Nonhip 2.51 (2.01-3.12)
Relative risk of fractures associated
with a history of prior fractures
Hip 1.97 (1.12-3.48)
Log-normal
Kanis et al34 (2004)
Nonhip 1.91 (1.50-2.43)
Relative risk of fractures during
osteoporosis treatment










Kothawala et al36 (2007)
and Koller et al37 (2020)
Zoledronic acidb 36 (23-50)
Relative risk of death associated
with a history of falls
1.3 (0.90-1.80) Log-normal Dunn et al
38 (1992)
Relative risk of death after
hip fractures
First year 3.7 (3.31-4.14)
Log-normal
Haentjens et al39 (2010)
Subsequent years 2.53 (1.81-3.54)
Relative risk of death after clinical
vertebral fractures
1.83 (1.80-1.86) Log-normal Lau et al
40 (2008)
Cost, $c
DXA 39.99 Gamma American College ofRheumatology41 (2020)
Physician visit 76.06 American College of
Rheumatology41 (2020)
Osteoporosis treatment












Gabriel et al46 (2002) and




Post–hip fracture state (per year) 11 736 Gamma Schousboe et al23 (2007)
(continued)
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calculated using BMD data from the 2005-2008 NHANES and a meta-analysis of cohort studies from
12 countries.32,33 The excess risks of fractures associated with a history of fractures were taken from
a meta-analysis of cohort studies from 11 countries.34
Treatment Effect
Relative risk reductions of fractures by osteoporosis treatment were taken from a meta-analysis of
clinical trials of bisphosphonates in men.35 We assumed that a history of falls did not alter the fracture
reduction benefit by osteoporosis treatment. The model used the reduction in nonvertebral fracture
rates as a surrogate for the reduction in hip, wrist, and humeral fracture rates.27 The fracture
reduction benefit was assumed to appear in the second year of therapy.54 The model incorporated a
linear decrease in the fracture reduction benefit during 5 years after its termination.27 Adherence to
alendronate and zoledronic acid treatment was based on meta-analyses of multiple observational
studies.36,37 The model adopted a conservative assumption that only those who completed a 5-year
course of osteoporosis treatment gained the fracture reduction benefit. Adverse effects of treatment
were not modeled based on a systematic review.16
Mortality
The background mortality rates were based on 2017 US life tables published by the National Center
for Health and Statistics.55 Excess mortality attributable to a history of falls was taken from the
Longitudinal Study on Aging.38 Excess mortality after hip fractures was taken from a meta-analysis
of cohort studies from 7 countries.39 Excess mortality after clinical vertebral fractures was taken from
a retrospective data analysis of Medicare claims.40 An alternate scenario excluding excess mortality
after clinical vertebral fractures was also tested in a scenario analysis.27
Costs
The costs of DXA and a physician visit were obtained from the 2020 Medicare National Average
Rates (Current Procedural Terminology [CPT] codes 77080 and 99213, respectively).41 The wholesale
acquisition costs of alendronate and zoledronic acid were used as the medication costs.42 Those who
did not adhere to alendronate therapy accrued the medication cost for only 6 months. Those who
did not adhere to zoledronic acid therapy accrued the medication cost for only the first year. Infusion
and related supply costs of zoledronic acid were taken from a US claim-based cost analysis.43 Costs
of the basic metabolic panel (CPT code 80048) and comprehensive dental examination (CPT code D
0150) were based on the national mean commercial rates.44,45 Acute costs of managing each type
of fracture were taken from a US claim-based cost analyses.46,47 The long-term cost of hip fractures
Table 1. Model Parameters (continued)
Parameter Value (range) Distribution Source
Utility multiplier
Fracture freea 0.84 (0.80-0.85)
Log-normal
Hanmer et al48 (2006) and




Svedbom et al50 (2018) and
Lesnyak et al51 (2020)






Svedbom et al50 (2018) and
Lesnyak et al51 (2020)
Clinical vertebral 0.85 (0.82-0.87)
Wrist 0.99 (0.97-1.00)
Humeral 0.89 (0.85-0.92)
Abbreviations: CMS, Centers for Medicare & Medicaid
Services; DXA, dual-energy x-ray absorptiometry.
a Age-specific variable. See the eTable in the
Supplement.
b Tested in a scenario analysis.
c Range is 50% to 200% of the base-case costs.
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(eg, increased admission to long-term care facilities) was incorporated.23 All costs were inflated to
2019 US dollars using the Consumer Price Index for Medical Care for All Urban Consumers.56
Quality of Life
The age-dependent, fracture-free utility values were based on EuroQol-5 Dimension (EQ-5D) scores
collected from nationally representative US community-dwelling samples.48 The utility multiplier
for a history of falls was calculated using a EQ-5D survey in Germany.49 The utility multiplier for each
type of fracture was taken from the International Costs and Utilities Related to Osteoporotic
Fractures Study.50,51 If individuals sustained a fracture, for example, their baseline utilities were
multiplied by the utility of that fracture event in the first year and by the utility of that postfracture
health state in subsequent years.
Model Validation
To assess its external validity, the model simulated the prognosis of men aged 50 years without a
history of falls receiving usual care. The predicted lifetime risk of hip fracture was 11%; clinical
vertebral fracture, 9%; wrist fracture, 3%; and humeral fracture, 3%. These predicted risks
approximated well with published estimates.57
Statistical Analysis
The analysis was designed and conducted from October 1, 2019, to September 30, 2020. We
measured health outcomes in quality-adjusted life-years (QALYs). The incremental cost-effectiveness
ratio (ICER) of a strategy was calculated as the additional cost of that strategy divided by its
additional health benefit compared with the competing strategy. Deterministic sensitivity analyses
were conducted on discount rates, age at screening, treatment characteristics (ie, treatment effect
during treatment and after discontinuation), medication treatment adherence, excess mortality after
fractures, treatment costs, fracture costs, and effect of fractures on utility. The 95% CI of each
parameter was obtained, when available; otherwise, 50% to 200% of the base-case estimates were
used. Because the reduction in nonvertebral fractures with treatment was used as a surrogate for
reduction in hip fracture rates, this assumption was tested rigorously in sensitivity analyses. A
probabilistic sensitivity analysis was also conducted in which the model was run using a value for each
parameter down randomly from the distribution assigned to that parameter. The model ran 100 000
iterations to generate a cost-effectiveness acceptability curve showing the probability that either
strategy was cost-effective using varying willingness-to-pay (WTP) thresholds.
Results
Base-Case Analysis
For the base-case population, 1876 men needed to undergo screening to prevent 1 hip fracture, and
746 men needed to undergo screening to prevent 1 major osteoporotic fracture (Table 2). The
screening strategy improved quality-adjusted survival by 0.0026 QALYs, increased costs by $87, and
had an ICER of $33 169/QALY gained. Therefore, the screening strategy would be preferred over
usual care at the conventional WTP threshold of $100 000/QALY gained.
Sensitivity Analyses
These results were sensitive to assumptions about the age at screening (Table 2). As the target
population became older, numbers needed to screen to prevent 1 hip fracture and 1 major
osteoporotic fracture would become smaller and the screening strategy would become increasingly
cost-effective. The screening strategy would become dominant (ie, more effective and less costly
than usual care) for men 77 years or older. These results were also sensitive to the assumption about
the treatment effect during osteoporosis treatment. Under the most conservative assumption about
the relative risk of nonvertebral fractures during osteoporosis treatment (ie, 0.90), the ICER for the
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screening strategy would slightly exceed the conventional WTP threshold of $100 000/QALY
gained. The screening strategy would be preferred over usual care for men 66 years or older. The
ICER for the screening strategy did not substantially change across a reasonable range of
assumptions tested in all other deterministic sensitivity analyses (Table 3).
Probabilistic Sensitivity Analysis
The result of the probability sensitivity analysis in the base-case population is displayed in the cost-
effectiveness acceptability curve (Figure 2). At the WTP threshold of $50 000/QALY gained, the
screening strategy would be cost-effective in 56.0% of stimulations; at $100 000/QALY gained,
90.8% of simulations; and at $200 000/QALY gained, 99.6% of simulations.
Scenario Analyses
If the reference for White men aged 20 to 29 years was applied for the diagnosis of osteoporosis, an
ICER for the screening strategy would decrease to $31 039/QALY gained. If zoledronic acid was
selected as a drug of choice when osteoporosis treatment was indicated, an ICER for the screening
strategy would increase to $52 653/QALY gained. If men with a history of a single fall in the past year
were targeted, an ICER for the screening strategy would increase to $34 705/QALY gained. If men
with a history of multiple falls in the past year were targeted, an ICER for the screening strategy
would decrease to $25 159/QALY gained for men with a history of 2 falls and $5478/QALY gained for
men with a history of at least 3 falls. If excess mortality after clinical vertebral fractures was excluded
from the model, an ICER for the screening strategy would increase to $36 360/QALY gained.
Therefore, across various scenarios tested, the screening strategy would remain preferred over usual
care at the conventional WTP threshold of $100 000/QALY gained.
Discussion
This study found that screening with DXA followed by treatment for those diagnosed with
osteoporosis would be reasonably cost-effective for men aged 65 years who have fallen at least once
in the past year. If the target population was older than 77 years, it would simultaneously improve
health outcomes and save money from the societal perspective. These findings were robust to wide
variations of the model assumptions and concur with previous cost-effectiveness analyses indicating
that screening could be justified when targeted to men at higher risk for osteoporotic fractures.23-26
These findings are also promising given the emerging evidence that population-based screening
using fracture risk assessment and DXA is effective to reduce hip and osteoporotic fractures in
postmenopausal women.19-22 The observed numbers needed to screen to prevent a hip and an
Table 2. Cost-effectiveness According to Age at Screening
Strategy
Number needed to screen
Cost, $ QALYs ICER, $/QALYHip fracture MOF
Aged 65 y (base case)
Usual care NA NA 6447 9.6146 Reference
Screening 1876 746 6534 9.6173 33 169
Aged 70 y
Usual care NA NA 7396 7.8295 Reference
Screening 739 393 7451 7.8339 12 631
Aged 75 y
Screening NA NA 8061 6.1953 Reference
Usual care 482 309 8094 6.2002 6670
Aged 80 y
Usual care NA NA 9017 4.6041 Dominated
Screening 183 104 8932 4.6152 Reference
Abbreviations: ICER, incremental cost-effectiveness
ratio; MOF, major osteoporotic fracture; NA, not
applicable; QALY, quality-adjusted life-year.
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osteoporotic fracture (ie, 272 and 247, respectively) from these clinical trials are comparable with our
model estimates for men aged 75 to 80 years.22
Determining whether the patient has fallen in the past year is the first step in preventing future
falls and the major injuries that can result from falling.58 Fall risk assessment is integrated into the
Welcome to Medicare examination and the Medicare Annual Wellness Visit.59 In a recent review
Table 3. One-Way Deterministic Sensitivity Analyses
Parameter ICER, $/QALY Range
Discount rate, % 19 477-51 655 0-6
Prevalence of osteoporosis, % 21 461-64 966 1.98-4.62
Relative risk of fracture on osteoporosis treatment
Clinical vertebral 28 034-80 949 0.11-1.51
Nonvertebral 16 765-104 340 0.40-0.90
Treatment benefit offset, y 22 013-67 222 0-10
Adherence to osteoporosis treatment, % 23 806-48 967 32-54
Relative risk of death after hip fracture
First year 33 053-33 277 3.31-4.14
Subsequent years 32 184-34 421 1.81-3.54
Relative risk of death after vertebral fracture 33 085-33 253 1.80-1.86
Cost, $
Osteoporosis treatment 29 557-40 392
50%-200% of the base-case
costs
Fracture event
Hip 25 986-36 760
Clinical vertebral 31 791-33 857
Wrist 32 911-33 298
Humeral 32 768-33 369
Post–hip fracture health state (per year) 20 208-39 649
Utility multiplier
Fracture event
Hip 33 019-33 320 0.53-0.57
Clinical vertebral 33 027-33 263 0.65-0.70
Wrist 33 157-33 181 0.82-0.84
Humeral 33 067-33 245 0.72-0.79
Postfracture health state
Hip 32 686-34 178 0.84-0.90
Clinical vertebral 32 369-33 581 0.82-0.87
Wrist 33 066-33 220 0.97-1.00
Humeral 32 756-33 485 0.85-0.92
Abbreviations: ICER, incremental cost-effectiveness
ratio; QALY, quality-adjusted life year.
Figure 2. Cost-effectiveness Acceptability Curve





























A range of willingness-to-pay (WTP) thresholds were
plotted on the horizontal axis against the probability
that either usual care or the screening strategy would
be cost-effective at that WTP threshold on the vertical
axis. QALY indicates quality-adjusted life-year.
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undertaken by the US Preventive Services Task Force, multifactorial interventions or single exercise-
based interventions were found to reduce fall risk, but their effect on fracture risk was not
significant.10 Fracture prevention could be achieved by screening and treatment for osteoporosis
without reducing the number of falls.60 These findings do not suggest that fall prevention measures
should not be included in patient management but do raise a concern that, for individuals with
significant skeletal risk factors, fall prevention measures alone might not be sufficient to reduce fall-
related fractures. On the other hand, combined with older age, the presence of osteoporosis
accounts for only one-third of all fracture cases in men.61 The BMD-based approach is likely to miss a
large number of individuals who do not have osteoporosis and have nonskeletal risk factors (eg, falls)
and is unlikely to reduce a large number of fractures. A combined approach to address both falls and
osteoporosis is not a new concept.62 Because fracture prevention is the ultimate goal, inclusion of
screening for osteoporosis into the fall prevention algorithm could potentially lead to a further
reduction of fractures in individuals who have fallen.63
Limitations
The study should be interpreted in light of several cautions. First, we assumed that the fracture
reduction efficacy by osteoporosis treatment was not altered by a history of falls. In a clinical trial of
clodronate in postmenopausal women,64 fall risk did not significantly affect its fracture reduction
efficacy. In a clinical trial of zoledronic acid in institutionalized, functionally impaired women with
osteoporosis,65,66 improvements in BMD were comparable to those observed in community-
dwelling, functionally unimpaired women. None of the clinical trials of bisphosphonates in men were
adjusted for their underlying fall risk.35 Therefore, we varied the assumption about treatment
effectiveness widely in sensitivity analyses. Second, the characterization of risk factors for fracture
that contribute significantly to fracture risk, beyond that provided by BMD, has stimulated the
development of risk assessment tools to determine a treatment threshold. The more adequately
evaluated tools include the Fracture Risk Assessment Tool (FRAX) tool (University of Sheffield),67
Garvan bone fracture risk calculator (Garvan Institute of Medical Research),68 and the QFracture risk
calculator (ClinRisk Ltd).69 Both the Garvan and QFracture tools include a history of falls, whereas
the FRAX tool does not. Recognizing the limitations of falls data in the current FRAX cohorts, an
expert panel recommended that FRAX probability might be modified to account for a history of falls,
with the output inflated by 30% for each past fall (for 5 falls).70 In this study, the model did not
consider these risk assessment tools to determine a treatment threshold because drug efficacy in
preventing fractures has been proven only in individuals with osteoporosis defined based on BMD or
fracture history.
Conclusions
The results of this economic evaluation suggest that for older men who have fallen at least once in the
past year, screening with DXA followed by treatment for those diagnosed with osteoporosis may be
a cost-effective use of resources. In clinical practice, fall history could be a useful cue to trigger
assessment for osteoporosis in men. The study also suggests that Medicare coverage of screening
with DXA could be expanded to older men with a history of falls.
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